CD33 and acute myeloid leukemia: In line with these findings, the German company Cellex Patient Treatment GmbH created a modular universal CAR platform called UniCAR, to generate adapter CARs which consists of two components: a targeting module (TM)-specific CAR for the initial T-cell engineering and a TM which redirects the Uni-CAR-T cells to a specific target (e.g., a CD33 or CD123 antigen on AML blasts).